CN109394819A - A kind of medical usage of flavone compound in gamboge - Google Patents
A kind of medical usage of flavone compound in gamboge Download PDFInfo
- Publication number
- CN109394819A CN109394819A CN201811084270.XA CN201811084270A CN109394819A CN 109394819 A CN109394819 A CN 109394819A CN 201811084270 A CN201811084270 A CN 201811084270A CN 109394819 A CN109394819 A CN 109394819A
- Authority
- CN
- China
- Prior art keywords
- gamboge
- flavone compound
- mouse
- drug
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940117709 gamboge Drugs 0.000 title claims abstract description 30
- 241000598860 Garcinia hanburyi Species 0.000 title claims abstract description 29
- -1 flavone compound Chemical class 0.000 title claims abstract description 26
- 229930003944 flavone Natural products 0.000 title claims abstract description 24
- 235000011949 flavones Nutrition 0.000 title claims abstract description 24
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 title claims abstract description 22
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 12
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims description 42
- 229940079593 drug Drugs 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 1
- 239000002253 acid Chemical class 0.000 claims 1
- 150000001447 alkali salts Chemical class 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000013376 functional food Nutrition 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 41
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 150000002632 lipids Chemical class 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 14
- 235000012000 cholesterol Nutrition 0.000 description 13
- 238000010171 animal model Methods 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 208000008589 Obesity Diseases 0.000 description 9
- 235000020824 obesity Nutrition 0.000 description 9
- 150000003626 triacylglycerols Chemical class 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 235000009200 high fat diet Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 229960004844 lovastatin Drugs 0.000 description 6
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 6
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 5
- 102000015779 HDL Lipoproteins Human genes 0.000 description 5
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 210000003038 endothelium Anatomy 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 101000988577 Homo sapiens 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108010074438 Sterol Regulatory Element Binding Protein 2 Proteins 0.000 description 3
- 102100026841 Sterol regulatory element-binding protein 2 Human genes 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000593508 Garcinia Species 0.000 description 2
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- GEZHEQNLKAOMCA-RRZNCOCZSA-N (-)-gambogic acid Chemical compound C([C@@H]1[C@]2([C@@](C3=O)(C\C=C(\C)C(O)=O)OC1(C)C)O1)[C@H]3C=C2C(=O)C2=C1C(CC=C(C)C)=C1O[C@@](CCC=C(C)C)(C)C=CC1=C2O GEZHEQNLKAOMCA-RRZNCOCZSA-N 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000598812 Garcinia tinctoria Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010000775 Hydroxymethylglutaryl-CoA synthase Proteins 0.000 description 1
- 102100028888 Hydroxymethylglutaryl-CoA synthase, cytoplasmic Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010090837 Member 5 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical compound [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- GEZHEQNLKAOMCA-UHFFFAOYSA-N epiisogambogic acid Natural products O1C2(C(C3=O)(CC=C(C)C(O)=O)OC4(C)C)C4CC3C=C2C(=O)C2=C1C(CC=C(C)C)=C1OC(CCC=C(C)C)(C)C=CC1=C2O GEZHEQNLKAOMCA-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- XGVJWXAYKUHDOO-UHFFFAOYSA-N galanthidine Natural products C1CN2CC3=CC=4OCOC=4C=C3C3C2C1=CC(O)C3O XGVJWXAYKUHDOO-UHFFFAOYSA-N 0.000 description 1
- GEZHEQNLKAOMCA-GXSDCXQCSA-N gambogic acid Natural products C([C@@H]1[C@]2([C@@](C3=O)(C\C=C(/C)C(O)=O)OC1(C)C)O1)[C@H]3C=C2C(=O)C2=C1C(CC=C(C)C)=C1O[C@@](CCC=C(C)C)(C)C=CC1=C2O GEZHEQNLKAOMCA-GXSDCXQCSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- QALPNMQDVCOSMJ-UHFFFAOYSA-N isogambogic acid Natural products CC(=CCc1c2OC(C)(CC=C(C)C)C=Cc2c(O)c3C(=O)C4=CC5CC6C(C)(C)OC(CC=C(C)/C(=O)O)(C5=O)C46Oc13)C QALPNMQDVCOSMJ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- XGVJWXAYKUHDOO-DANNLKNASA-N lycorine Chemical compound C1CN2CC3=CC=4OCOC=4C=C3[C@H]3[C@H]2C1=C[C@H](O)[C@H]3O XGVJWXAYKUHDOO-DANNLKNASA-N 0.000 description 1
- KQAOMBGKIWRWNA-UHFFFAOYSA-N lycorine Natural products OC1C=C2CCN3C2C(C1O)c4cc5OCOc5cc34 KQAOMBGKIWRWNA-UHFFFAOYSA-N 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000009125 negative feedback regulation Effects 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses flavone compound a kind of in gamboge prevention or treatment hyperlipidemias, the purposes of atherosclerosis.
Description
Invention field
The present invention relates to the new opplication field of flavone compound a kind of in gamboge, disclose its preparation hyperlipidemia,
Application in atherosclerosis drug.
Background of invention
Atherosclerosis refers to lipid, the carbon hydrate of aorta, medium-sized artery (such as brain, kidney, coronary endometrium)
Object and blood constituent deposition necrosis form atheroma, smooth muscle cell and collagen fiber hyperplasia, calcification and hardening, form thrombus, lead
Cause official jargon occlusion.Thus caused cardiovascular and cerebrovascular disease seriously endangers human health, can also result in sometimes hypertension, diabetes,
The generation of the diseases such as coronary heart disease.Modern medicine study, which shows hyperlipidemia, and disorders of lipid metabolism is leads to atherosclerosis
(AS) Major Risk Factors formed.
In order to comply with the development trend of traditional Chinese medicine research, the research of chemical composition of Chinese materia medica becomes the master of modernization of cmm
Want one of content.Currently, improving with medical research condition, athero- using traditional Chinese medicine treatment hyperlipidemia, artery
The developmental research of the diseases such as sclerosis and clinic achieve significant progress.According to the literature, the main of blood lipid is reduced in Chinese medicine
Effective component has: flavones, protein, active polysaccharide, unsaturated fatty acid, glycosides, polyphenol, Lovastatin, wherein flavonoids
If closing the effect that owner realizes reducing blood lipid by antioxidation.
Chinese medicine gamboge is to secrete after Garcinia maingayii gamboge (Garcinia hamburgy Hook.f.) trunk cut wound
Gum resin.It is cool in nature, it is sour, puckery, it is toxic.Have effects that detumescence detoxification, hemostasis desinsection, except tinea.Chemical constitution study shows gamboge
Mainly contain the flavone compound using gambogicacid as representative.Gamboge has antitumor, enhancing immunity of organisms, antibacterial, anti-inflammatory
And antivirus action, clinic is mainly used for treating tumour, including breast cancer, liver cancer, lymphosarcoma, myeloma, alimentary canal swell
Tumor, tumor in respiratory system and tumor of prostate etc..Flavone compound is the antitumor main matter basis of gamboge, but should
Whether class compound has reducing blood lipid, treatment Atherosclerosis there is not yet any report.The present invention has found from gamboge
A kind of flavone compound has the drug effect of lipid-loweringing, and attempts in terms of molecular biology field, gene level to it
Carry out careful research.
Summary of the invention
The present invention is intended to solve the above problems and provides a kind of flavone compound in gamboge and preventing and treating artery congee
Sample hardens the drug effect in drug.
To achieve the goals above, first passage pharmacological evaluation has found a kind of flavonoid to the present invention from gamboge
Object has good therapeutic effect to the obesity mice that high fat diet induces.System research has been carried out to this zoopery, has been sent out
Existing: in the case that mouse diet hardly changes, this compound can obviously lower the weight of obesity mice, in blood always
Cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL-C) are horizontal, and increasing high density lipoprotein (HDL-C) is horizontal.
Meanwhile TG, TC level are significantly reduced in excrement.Show this chromocor compound for treatment hyperlipidemia and artery congee
The research of sample hardening is meaningful.
The present invention this flavone compound in invention gamboge, which has, prevents and treats hyperlipidemia, Atherosclerosis
Chemical drug effect basis on, also disclose its as drug available auxiliary material have solvent, adhesive, disintegrating agent, corrigent,
The conventional excipients such as toner.
Due to hyperlipidemia cause atherosclerosis along with some serious cardiovascular and cerebrovascular diseases generation, this
Invention also discloses the composition for treating these diseases, and drug dose range is: 30mg/kg-60mg/kg.
In order to make it easy to understand, purposes of the invention is described in detail below by specific embodiments and the drawings.It needs
It wants it is emphasized that specific embodiments and the drawings are merely to explanation, it is clear that those skilled in the art can be according to herein
Illustrate, carrying out various amendments or change, these modifications and variations to the present invention will also be included within the scope of the invention.
Attached drawing
The mouse model changes of weight curve of a kind of flavone compound to induction high in fat in Fig. 1 gamboge
The mouse model food-intake change curve of a kind of flavone compound to induction high in fat in Fig. 2 gamboge
The influence of a kind of flavone compound to the blood lipid levels of the mouse of induction high in fat in Fig. 3 gamboge
The influence of a kind of flavone compound to the excrement lipid level of the mouse of induction high in fat in Fig. 4 gamboge
The influence of a kind of flavone compound to related gene in animal model liver high in fat in Fig. 5 gamboge
Data recordation of the invention is in following table:
Influence of the 1. hydrochloric acid lycorine of table to the mouse model food-intake of induction high in fat
Content of triglyceride in 2. blood plasma of table
Total cholesterol level in 3. blood plasma of table
4 blood plasma middle-high density lipoprotein content of table
Low-density lipoprotein content in 5. blood plasma of table
6. fasting blood sugar level of table
Area value under 7. oral glucose tolerance line of table
Face amount under 8. insulin resistant line of table
Specific embodiment
Embodiment one
Experiment purpose: influence of certain chromocor compound to inducing mouse weight high in fat and diet in research gamboge
Experimental animal: using C57BL/6J mouse, SPF grades, male, weight (20 ± 2) g
Experimental method: after mouse adapts to one week environment, mouse is randomly divided into two groups, first group 8, is given normal
Feed, as blank control group.Remaining mouse (32) is divided into 4 groups, give high lipid food (19.4% protein of feed heat,
0.6% carbohydrate, 60% fat).Respectively as model group, positive drug group (60mg/kg), low concentration medicine group
(30mg/kg), high concentration medicine group (60mg/kg).Then, by the way of stomach-filling, it then follows the dosage of 2ml/20g, point
Each group is not given pours into PBS solution, CMC-Na solution, Lovastatin solution (30mg/kg), drug low concentration solution (30mg/
Kg), high drug concentration solution (60mg/kg).All mouse freely ingest, drink water.It is continuous to feed 7 weeks.
Medicine ordinance method: with 0.5% CMC-Na solution ultrasonic dissolution.
Mouse observation index during administration:
1. the ordinary circumstance of animal
Experimental animal, illumination 12h night 12h, free diet drinking-water, animal state during experiment.
2. recording mouse food-intake, a weight weekly
The result is shown in Figure 1, Fig. 2, table 1.
The mouse model food-intake data of the induction high in fat of table 1.
Analysis of experimental results: during experiment, the mouse state of mind and active state are normal.Fig. 1 display model group phase
It is significantly increased than normally organizing weight, prompts modeling success, weight significantly reduces after giving mouse drug effect 7 weeks.Fig. 2 and table
1. data show that the dietary amount of each group mouse does not have significant changes, show that the variation of mouse weight and dietary amount do not have much passes
System, the effect for prompting the reduction of mouse weight to be likely to drug performance cause.
Embodiment two
A kind of experiment purpose: the influence of flavone compound to inducing mouse blood lipid high in fat in research gamboge
Experimental animal: using C57BL/6J mouse, SPF grades, male, weight (20 ± 2) g
Experimental method: after mouse adapts to one week environment, mouse is randomly divided into two groups, first group 8, is given normal
Feed, as blank control group.Remaining mouse (32) is divided into 4 groups, give high lipid food (19.4% protein of feed heat,
0.6% carbohydrate, 60% fat).Respectively as model group, positive drug group (60mg/kg), low concentration medicine group
(30mg/kg), high concentration medicine group (60mg/kg).Then, by the way of stomach-filling, it then follows the dosage of 2ml/20g, point
Each group is not given pours into PBS solution, CMC-Na solution, Lovastatin solution (30mg/kg), drug low concentration solution (30mg/
Kg), high drug concentration solution (60mg/kg).All mouse freely ingest, drink water.Continuous to feed 6 weeks, eyeball takes blood, neck
Vertebra dislocation is put to death, and is taken out respective organization and analyzed.
Medicine ordinance method: with 0.5% CMC-Na solution ultrasonic dissolution.
Mouse observation index during administration:
The ordinary circumstance of animal
1. experimental animal, illumination 12h night 12h, free diet drinking-water, animal state during experiment.
2. blood lipids: taking the eye socket serum of mouse, and analyze the horizontal of its LDL-C, HDL-C, TG, TC and become
Change.
As a result it is shown in Table 2, table 3, table 4, table 5, Fig. 3 (unit: mM) respectively.
Table 2: the cholesterol data (unit: mM) of drug-treated high fat diet obesity-induced mice blood
The * P < 0.05 compared with model group, * * P < 0.01, * * * P < 0.001
Table 3: the triglycerides data of drug-treated high fat diet obesity-induced mice blood
The * P < 0.05 compared with model group, * * P < 0.01
Table 4: the low-density lipoprotein data of drug-treated high fat diet obesity-induced mice blood
The * P < 0.05 compared with model group, * * P < 0.01, * * * P < 0.001
Table 5: the high-density lipoprotein data of drug-treated high fat diet obesity-induced mice blood
The * P < 0.05 compared with model group, * * P < 0.01
Analysis of experimental results: the experimental result of mouse is examined using t and carries out statistical analysis, the results are shown in Table 2/3/4/
5, Fig. 2/3/4/5.It was found that this compound can obviously reduce total cholesterol in blood (TC), triglycerides (TG), low in gamboge
Density lipoprotein (LDL-C) is horizontal, the expression of increasing high density lipoprotein (HDL-C).Thus infer, such chromocor compound
It is obvious to hyperlipidemia improvement result effect, there is significant statistical difference.
Embodiment three
Experiment purpose: influence of this compound to lipid in animal model excrement high in fat in research gamboge
Experimental animal: C57BL/6J mouse, male, weight (20 ± 2) g are used.
Experimental method: after mouse adapts to one week environment, mouse is randomly divided into two groups, first group 8, is given normal
Feed, as blank control group.Remaining mouse (32) is divided into 4 groups, give high lipid food (19.4% protein of feed heat,
0.6% carbohydrate, 60% fat).Respectively as model group, positive drug group (60mg/kg), low concentration medicine group
(30mg/kg), high concentration medicine group (60mg/kg).Then, by the way of stomach-filling, it then follows the dosage of 2ml/20g, point
Each group is not given pours into PBS solution, CMC-Na solution, Lovastatin solution (30mg/kg), drug low concentration solution (30mg/
Kg), high drug concentration solution (60mg/kg).All mouse freely ingest, drink water.It is continuous to feed 6 weeks.At cervical dislocation
Extremely, it and takes out liver organization and saves into -80 DEG C of refrigerators so as to subsequent analysis.
Medicine ordinance method: with 0.5% CMC-Na solution ultrasonic dissolution.
Mouse observation index during administration:
1. experimental animal, illumination 12h night 12h, free diet drinking-water, animal state during experiment；
The mouse liver of collection is taken out, the whole extraction for carrying out mouse liver albumen on ice.By albumen after extraction
It is divided into two parts, a part carries out protein quantification using the method for BCA protein quantification, and another part is according to kit specification
TG, TC level of mouse liver are detected.
As a result it is shown in Table 6, table 7, Fig. 4 respectively.Unit: mg/g
Table 6: the cholesterol data of drug-treated high fat diet obesity-induced mice liver
The * P < 0.05 compared with model group, * * P < 0.01
Table 7: the triglycerides data of drug-treated high fat diet obesity-induced mice liver
The * P < 0.05 compared with model group, * * P < 0.01
Analysis of experimental results: the data of table 6/7 show, compared to model group, no matter high low dosage administration group mouse liver
In total cholesterol, triglyceride levels are all remarkably decreased.This prompts this chromocor compound to have alleviation to the accumulation of liver lipids
Effect.Further experiments have shown that also needing to illustrate by experiments such as H&E dyeing.
Example IV
Experiment purpose: influence of this compound to related gene in animal model liver high in fat in research gamboge
Experimental animal: C57BL/6J mouse, male, weight (20 ± 2) g are used.
Experimental method: after mouse adapts to one week environment, mouse is randomly divided into two groups, first group 8, is given normal
Feed, as blank control group.Remaining mouse (32) is divided into 4 groups, give high lipid food (19.4% protein of feed heat,
0.6% carbohydrate, 60% fat).Respectively as model group, positive drug group (60mg/kg), low concentration medicine group
(30mg/kg), high concentration medicine group (60mg/kg).Then, by the way of stomach-filling, it then follows the dosage of 2ml/20g, point
Each group is not given pours into PBS solution, CMC-Na solution, Lovastatin solution (30mg/kg), drug low concentration solution (30mg/
Kg), high drug concentration solution (60mg/kg).All mouse freely ingest, drink water.It is continuous to feed 6 weeks.At cervical dislocation
Extremely, it and takes out liver organization and saves into -80 DEG C of refrigerators so as to subsequent analysis.
Medicine ordinance method: with 0.5% CMC-Na solution ultrasonic dissolution.
Mouse observation index during administration:
1. experimental animal, illumination 12h night 12h, free diet drinking-water, animal state during experiment；
2. the mouse liver of collection is taken out, the whole extraction for carrying out mouse liver RNA on ice.It surveys RNA concentration and determines
Amount.RNA is reversed to cDNA, carries out fluorescent quantitative PCR experiment, detect some SREBPs genes related with lipid-metabolism and
The expression of its target gene.
As a result Fig. 5 is seen respectively.
Analysis of experimental results: statistics indicate that, the mRNA level in-site of SREBP-2 is by under significant in administration group mouse liver tissue
It adjusts, while being had by a series of downstream genes of the participation cholesterol biosynthesis process of SREBP-2 regulation and enzyme such as HMGCS, SS etc.
A degree of decline, but the same transcriptional level as the target gene HMGCR of SREBP-2 is raised, this phenomenon and
The result of HMGCR specific inhibitor Lovastatin group is consistent, this not only shows HMGCR, and there are the compensation of negative-feedback regu- lation
Mechanism, and also indicate that the mechanism of action of this flavone compound may have similarity with Lovastatin.In addition, with rouge egg
The relevant gene such as apolipoprotein E of white metabolism has significant up-regulation to act on, and to ApoB and sterol transporter ABCG5
MRNA level in-site then have downward effect, show that this compound has the function of that mouse blood lipid is promoted to remove, and can be reduced small
The absorption of intestines exogenous free cholesterol.
Since high-density lipoprotein (HDL-C) main function is to be metabolized cholesterol into liver from blood transportation,
Referred to as " good " cholesterol, the cholesterol of antiatherosclerosis.Low-density lipoprotein (LDL-C) is atherosclerotic plaque
The main component of block, when various risk factors (such as hypertension, diabetes) cause blood vessel endothelium injury, cell expression is glutinous
Attached molecule, adherent mononuclear cells migration are changed into huge saliva cell to subendothelial.Enter endothelium also by the blood vessel endothelium of damage
Under, Pao Droplets cell is formed after being swallowed by macrophage, is deposited on vascular wall and is formed atherosclerosis Lipid Plaque.
In conclusion the C57BL/6J Mice model of obesity based on high fat diet induction, finds there is a kind of flavones in gamboge
Lipid level in blood and liver can be significantly reduced in class compound, while reducing lipid level in excrement.In addition, it may be used also
To regulate and control a series of transcriptional level of SREBP target genes.These data, which show such compound not only, has preferable lipid-loweringing
Activity, and can be used as treatment or control the potential drug of hyperlipidemia, atherosclerosis, but the specific work of its lipid-loweringing
It is also needed further to study with mechanism, conclusions are that its following correlative study and exploitation provide certain reference frame.
High-density lipoprotein (HDL-C) main function is to be metabolized cholesterol into liver from blood transportation, therefore claimed
For " good " cholesterol, the cholesterol of antiatherosclerosis.Low-density lipoprotein (LDL-C) is atherosclerotic plaque
Main component, when various risk factors (such as hypertension, diabetes) cause blood vessel endothelium injury, cell expression is sticked point
Son, adherent mononuclear cells migration are changed into huge saliva cell to subendothelial.Enter subendothelial, quilt also by the blood vessel endothelium of damage
Pao Droplets cell is formed after macrophage phagocytosis, vascular wall is deposited on and forms atherosclerosis Lipid Plaque.
Claims (4)
1. a kind of flavone compound is used to prepare the composition for treating or preventing hyperlipidemia in gamboge.
2. a kind of flavone compound is used to prepare the composition for treating or preventing atherosclerosis in gamboge.
3. a kind of flavone compound is used to prepare the composition for treating or preventing nonalcoholic fatty liver in gamboge.
4. in gamboge a kind of flavone compound be used to prepare treat or prevent hyperlipidemia, hyperglycemia, nonalcoholic fatty liver,
The composition of any one or more in diabetes B, it is characterised in that:
For flavone compound a kind of in commercially available or gamboge by known method preparation or its pharmaceutical salts, hydrate or anhydride；
Wherein a kind of flavone compound pharmaceutical salts include basic salt, acid salt, such as sodium salt, sylvite and calcium salt, Malaysia in gamboge
Hydrochlorate, citrate；
Composition is made: drug, health care product or functional food, excipient or carrier are common in pharmacy or field of food
Excipient or carrier, such as diluent, disintegrating agent, lubricant etc..
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811084270.XA CN109394819A (en) | 2018-09-14 | 2018-09-14 | A kind of medical usage of flavone compound in gamboge |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811084270.XA CN109394819A (en) | 2018-09-14 | 2018-09-14 | A kind of medical usage of flavone compound in gamboge |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109394819A true CN109394819A (en) | 2019-03-01 |
Family
ID=65465028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811084270.XA Pending CN109394819A (en) | 2018-09-14 | 2018-09-14 | A kind of medical usage of flavone compound in gamboge |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109394819A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998017671A1 (en) * | 1996-10-22 | 1998-04-30 | Ravi Shrivastava | Magnesium (-)hydroxycitrate, method of preparation, applications, and compositions in particular pharmaceutical containing same |
| CN103816147A (en) * | 2014-03-14 | 2014-05-28 | 吉林农业大学 | Novel pharmaceutical uses of garcinolic acid, neogambogic acid and composition of garcinolic acid and neogambogic acid |
| CN106236815A (en) * | 2016-08-03 | 2016-12-21 | 中国农业大学 | Resina garciniae extract application in preventing and treating diabetes |
| CN107412223A (en) * | 2017-05-22 | 2017-12-01 | 中国药科大学 | A kind of medical usage of Oxygenic heterocyclic compounds |
-
2018
- 2018-09-14 CN CN201811084270.XA patent/CN109394819A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998017671A1 (en) * | 1996-10-22 | 1998-04-30 | Ravi Shrivastava | Magnesium (-)hydroxycitrate, method of preparation, applications, and compositions in particular pharmaceutical containing same |
| CN103816147A (en) * | 2014-03-14 | 2014-05-28 | 吉林农业大学 | Novel pharmaceutical uses of garcinolic acid, neogambogic acid and composition of garcinolic acid and neogambogic acid |
| CN106236815A (en) * | 2016-08-03 | 2016-12-21 | 中国农业大学 | Resina garciniae extract application in preventing and treating diabetes |
| CN107412223A (en) * | 2017-05-22 | 2017-12-01 | 中国药科大学 | A kind of medical usage of Oxygenic heterocyclic compounds |
Non-Patent Citations (4)
| Title |
|---|
| YONG LIU，等: "Gambogic acid induces G0/G1 cell cycle arrest and cell migration inhibition via suppressing PDGF receptor β tyrosine phosphorylation and Rac1 activity in rat aortic smooth muscle cells", 《JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS》 * |
| ZU-GUO ZHENG，等: "Anhydroicaritin improves diet-induced obesity and hyperlipidemia and", 《BIOCHEMICAL PHARMACOLOGY》 * |
| 周焰，等: "脂肪肝与高血压病、高脂血症、糖尿病以及体重指数相关性分析", 《现代消化及介入诊疗》 * |
| 赵慧萍: "藤黄中黄酮类化合物对高胆固醇血症", 《国外医药·植物药分册》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1759834B (en) | Application of berberine or associated with Simvastatin in preparing product for preventing or curing disease or symptom related to blood fat | |
| CN104161749A (en) | Application of polymethoxyflavone and its derivatives in prevention and treatment of low SIRT6 level related diseases | |
| CN101132789A (en) | Compounds having lipid lowering properties | |
| KR102612706B1 (en) | Composition for modifying a clock gene expression | |
| CN104983737B (en) | Pharmaceutical composition and its application in preparing prevention atherosclerosis, dyslipidemia drug | |
| CN109394819A (en) | A kind of medical usage of flavone compound in gamboge | |
| CN106727480B (en) | Fex-3 is preparing the application in anti-obesity drug | |
| CN106727507B (en) | The medical usage of Praeruptorin B | |
| CN104415135B (en) | The purposes of hydroxyl polymethoxyflavone class compound and/or its derivative | |
| CN113143962B (en) | A pharmaceutical composition for treating hyperlipidemia, and its preparation method | |
| CN109771411A (en) | Dihydroquercetin is used to prepare the purposes in the drug for the treatment of fatty liver | |
| CN106619605A (en) | Medicinal application of corylin | |
| CN108815505A (en) | Improve the composition that middle-aged and the old's bone density and osteoarticular function avoid waist-leg from knotting | |
| CN1714832A (en) | Medicinal composition with synergetic function | |
| CN106798738B (en) | Purposes of the Isopsoralen in preparation treatment hyperlipidemia | |
| CN106806365B (en) | Purposes of the psoralen in preparation treatment hyperlipidemia | |
| CN110882286A (en) | Application of wall-removed ganoderma lucidum spore powder | |
| CN105726693B (en) | Application of peach kernel oil in preparation of blood fat reducing medicine and health care product | |
| CN110548020B (en) | Application of spermidine in preparation of medicine for treating aortic aneurysm | |
| CN108403881A (en) | A kind of pharmaceutical composition for treating senile dementia and preparation method thereof and purposes | |
| CN1569868A (en) | Pineapple flavonoid glycoside compound and its use | |
| CN109195596A (en) | Composition and its application method | |
| EP3466433B1 (en) | Triacetyl-3-hydroxyl phenyl adenosine for use in treating acute vascular inflammations | |
| CN107114764A (en) | A kind of new application of composition | |
| US20200376003A1 (en) | Pharmaceutical composition for preventing or treating cholesterol gallstone comprising ursodeoxycholic acid (udca) and omega-3 fatty acid, and process for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190301 |